1yy9
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:1yy9.gif|left|200px]] | [[Image:1yy9.gif|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_1yy9", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | + | or leave the SCENE parameter empty for the default display. | |
| - | | | + | --> |
| - | | | + | {{STRUCTURE_1yy9| PDB=1yy9 | SCENE= }} |
| - | + | ||
| - | + | ||
| - | }} | + | |
'''Structure of the extracellular domain of the epidermal growth factor receptor in complex with the Fab fragment of cetuximab/Erbitux/IMC-C225''' | '''Structure of the extracellular domain of the epidermal growth factor receptor in complex with the Fab fragment of cetuximab/Erbitux/IMC-C225''' | ||
| Line 36: | Line 33: | ||
[[Category: Schmitz, K R.]] | [[Category: Schmitz, K R.]] | ||
[[Category: Wiltzius, J J.W.]] | [[Category: Wiltzius, J J.W.]] | ||
| - | [[Category: | + | [[Category: Antigen:antibody complex]] |
| - | [[Category: | + | [[Category: Antitumor]] |
| - | [[Category: | + | [[Category: Cell surface receptor]] |
| - | [[Category: | + | [[Category: Drug]] |
| - | [[Category: | + | [[Category: Fab fragment]] |
| - | [[Category: | + | [[Category: Glycoprotein]] |
| - | [[Category: | + | [[Category: Tyrosine kinase]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 16:57:14 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 13:57, 3 May 2008
Structure of the extracellular domain of the epidermal growth factor receptor in complex with the Fab fragment of cetuximab/Erbitux/IMC-C225
Contents |
Overview
Recent structural studies of epidermal growth factor receptor (EGFR) family extracellular regions have identified an unexpected mechanism for ligand-induced receptor dimerization that has important implications for activation and inhibition of these receptors. Here we describe the 2.8 angstroms resolution X-ray crystal structure of the antigen binding (Fab) fragment from cetuximab (Erbitux), an inhibitory anti-EGFR antibody, in complex with the soluble extracellular region of EGFR (sEGFR). The sEGFR is in the characteristic "autoinhibited" or "tethered" inactive configuration. Cetuximab interacts exclusively with domain III of sEGFR, partially occluding the ligand binding region on this domain and sterically preventing the receptor from adopting the extended conformation required for dimerization. We suggest that both these effects contribute to potent inhibition of EGFR activation.
Disease
Known disease associated with this structure: Adenocarcinoma of lung, response to tyrosine kinase inhibitor in OMIM:[131550], Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in OMIM:[131550], Nonsmall cell lung cancer, susceptibility to OMIM:[131550]
About this Structure
1YY9 is a Single protein structure of sequence from Homo sapiens and Mus musculus/homo sapiens. Full crystallographic information is available from OCA.
Reference
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab., Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM, Cancer Cell. 2005 Apr;7(4):301-11. PMID:15837620 Page seeded by OCA on Sat May 3 16:57:14 2008
